Search results
Found 639 matches for
What about Exclusion?
Monday, 27 October 2025, 10am to 11.30am
Public Discussion event as part of our ‘What about Exclusion?’ series, on Censorship and Self-Censorship.
Coming to an End- An interactive museum experience
Thursday, 06 November 2025 to Saturday, 15 November 2025, 10am - 5pm
Take part in a self-guided museum trail, hosted at the Ashmolean Museum, exploring issues of death, dying and end-of-life care. Adapted from an innovative, award-winning trail forming part of the Oxford medical curriculum, this activity is co-created by a multidisciplinary team spanning the humanities and medical sciences divisions and including the perspectives of expert patient tutors. You can also attend a one-off public discussion event exploring death across different cultural contexts of a diverse society hosted by our panel of experts.
Embodiment and Experience: An inter-generational dialogue on Experience, Values and Disruption in Mental Health
Friday, 15 August 2025, 9am to 5pm
Exploring Ethics with the London International Youth Science Forum
Tuesday, 29 July 2025, 12.45pm to 1.45pm
2025 Co-production session with NeurOx Young People's Advisory Group
Tuesday, 08 July 2025, 5pm to 6pm
Bioethics Laboratory at Wild Conservation and Research Unit
Wednesday, 02 July 2025, 12pm to 1.30pm
Determining a role for Patient and Public Involvement and Engagement (PPIE) in genomic data governance for cancer care
Abstract Comprehensive collections of cancer data, including genomic data, are needed to improve cancer risk prediction and treatments. A recent government review, Better, Broader, Safer: Using health data for research and analysis, has argued for high-quality Patient and Public Involvement and Engagement (PPIE) for ethical data use. In this paper we determine a role and justification for PPIE to govern uses of genomic data in fields like cancer. First, we analyse two public attitudes studies about the role of PPIE in genomics governance. Second, we characterise two ethically-significant features of the context of governing genomic data: 1) data aggregation leading to novel group formation, and 2) the hybrid territory of genomic cancer data uses. Thirdly, we bring together these aspects to describe a fully determined role for PPIE within an approach to governing cancer genomic data, which is tailored to major areas of ethical consideration. Our account is a novel interpretation of what PPIE is for in governance, how it may foster public support and how its success in so doing depends on it being tailored to context.